Kein Folientitel - the Leibniz Institute on Aging



Kein Folientitel - the Leibniz Institute on Aging
General information
Altes Schloss Dornburg
07778 Dornburg
Program committee:
Aria Baniahmad
Alexander Berndt
Yuan Chen
Joachim Clement
Matthias Dürst
Karl-Otto Greulich
Otmar Huber
Kerstin Junker
Thomas Knösel
Thomas Liehr
Iver Petersen
Ingo Runnebaum
Ferdinand von Eggeling
Zhao-Qi Wang
Interdisziplinäres Zentrum für Klinische Forschung – Schwerpunkt Onkologie
in collaboration with Fritz-Lipmann-Institut (FLI) Jena, UniversitätsTumorZentrum
(UTC) Jena, Jena School of Molecular Medicine, Graduierten-Akademie Jena
Iver Petersen, Institute of pathology, Ziegelmühlenweg 1, UKJ, 07740 Jena
Tel.: 03641-933 120, Fax: 03641-933111
Assistance: Robert Köllner
Email: [email protected]
Robert Köllner, email: [email protected]
Participation fee:
will be served after the symposium within the coutryard or the castle
depending on the weather (catering by „Zur Noll“)
If you do not attend the dinner please let us know in advance by email to
[email protected]
Postgraduate-Symposium on Cancer Research
Doktoranden-Symposium zur Krebsforschung
Samstag, 9. Mai 2009
Altes Schloss Dornburg (Kaisersaal)
9.00 Uhr
9.15 Uhr
Wellcome address
Prof. Dr. Klaus Benndorf
Dean of the medical faculty
Universitätsklinikum Jena (UKJ)
9.30 Uhr
Biomarkers in Cancer diagnostics, prognosis and therapy
Chairs: Iver Petersen, Ingo Runnebaum
1. Prevalence of HPV in tonsillar carcinoma (A38)
Felix Glombitza, Institute of Pathology, UKJ
2. CARS – An emerging technique for biomedical imaging (A29)
Nadine Vogler, Institut für Physikalische Chemie, FSU
3. Prognostic indicators of metastasis in patients with advanced bladder cancer (A27)
Rico Pilchowski, Clinic of Urology, UKJ
4. The expression of glutamat and NMDAR1 correlates with the WHO grade and is upregulated at the
tumor-brain-interface (A37)
Anja Fisker, Clinic of neurosurgery, UKJ
5. Detection of tumor stem cells among circulating epithelial tumor cells (CETC) (A13)
Katya Hekimian, Clinic of Internal Medicine II (KIM II), UKJ
6. Characterization of CD90-positive cells in the peripheral blood of tumor-patients (A22)
Kathleen Wagner, KIM II, UKJ
7. Translational control reporter systems to screen for anti-cancer drugs (A2)
Anna Bremer, Fritz-Lipmann-Institute (FLI)
8. Proteomic patterns to predict therapy response to immunochemotherapy in RCC-patients (A18)
Martina Walter, Clinic of Urology, UKJ
9. Screening of Cytotoxicities and Pharmacological Investigations of Phosphine-Dithiolato-Platinum(II)
Complexes (A57)
Claudia Rothenburger, Institut für Anorganische/Analytische Chemie, FSU
11.00 Uhr
11.30 Uhr
Tumor cell interaction and microenvironment
Chairs: Alexander Berndt, Joachim Clement
10. Influence of polysaccharide backbones on the interaction with human cells (A36)
Jana Wotschadlo, Kompetenzzentrum Polysaccharidforschung, FSU
11. Down-regulation of desmocollins in lung and colon carcinomas (A4)
Tiantian Cui, Institute of Pathology, UKJ
12. Stromal organization of fibronectin and tenascin-C variants – implications for diagnostic and
therapeutic use (A8)
Robert Köllner, Institute of Pathology, UKJ
13. BMPs in Hepatocellular Carcinoma – Modulation of thrombin induced cell migration (A11)
Tina Baumann, KIM II, UKJ
14. Influence of urinary bladder carcinoma cells on tumour associated fibroblasts (A16)
Astrid Enkelmann, Clinic of Urology, UKJ
15. Expression control of matrix metalloproteinase MMP-1 in colorectal carcinoma cells (A52)
A. Müller, Institute of Biochemistry II, UKJ
12.30 Uhr
Break with lunch snack
13.30 Uhr
Poster session I
Chairs: Thomas Liehr, Yuan Chen
15. Molecular cytogenetic characterization of AML patients with trisomy 8 (A3)
Philipp Kempf, Institute of Human Genetics, UKJ
16. Interphase FISH analysis of epitheloid haemangioendothelioma (A20)
Cornelius Wölfel, Institute of Pathology, UKJ
17. Core classification and DNA ploidy of angiosarcoma (A50)
Christina Nitz, Institute of Pathology, UKJ
18. Getting cells from individual colon cancer patients (A12)
Anne Wilhelm, FLI
19. Isolation and enrichment of rare cells with an immunomagnetic cell selection system (A23)
Kathleen Wagner, KIM II, UKJ
20. Characterization of circulating tumor cells by single cell RT-PCR (A19)
Susanne Grimm, KIM II, UKJ
21. Do cancer cells mimic stem cells strategy to be immortal? (A42)
Laura Peruch Aznar, FLI
22. Vibrational Spectroscopy for in vivo diagnosis in neurosurgery (A34)
Norbert Bergner, Institut für Physikalische Chemie, FSU
23. Monoclonal antibodies directed against the E7 oncoprotein of HPV45 (A15)
Sebastian Hölters, Clinic of gynecology, UKJ
24. Evaluation of novel mAb for the detection of dysplastic cells (A48)
Julia Kühnemund, Clinic of gynecology, UKJ
25. Identification of serum protein patterns in patients with penile carcinoma (A32)
Wulf Dieker, Clinic of urology, UKJ
26. Expression of Proteinase-Activated Receptors (PAR) 1-4 in Human Cancer (A58)
Andrea Elste, Institute of pathology, UKJ
27. Identification of DNA-Methylation Patterns in Tumor-Associated Stroma Cells in Cervical Cancer
Daniel Steinbach, Clinic of gynecology, UKJ
28. Identification of specific protein patterns in tumor tissue for prediction of immunochemotherapy
response (A21)
Christian Heinze, Clinic of urology, UKJ
Poster Session II
Chairs: Ferdinand von Eggeling, Thomas Knösel
29. Global epigenetic changes by HDAC inhibitors (A43)
Florian Beil, Institute of Human Genetics, UKJ
30. Novel interaction partners for the tumor suppressor p33ING1 suggest a role in prostate cancer (A35)
Susanne Jennek, Institute of Human Genetics, UKJ
31. Novel steroidal compounds as complete androgen antagonists inhibit prostate cancer cell growth
Undine Schubert, Institute of Human Genetics, UKJ
32. The peptide aptamer based corepressor T-Pep 513 inhibits prostate cancer cell growth (A53)
Maria Heinssmann, Institute of Human Genetics, UKJ
33. Specific metastasis-associated miRNA expression in clear cell renal cell carcinoma (A33)
Joana Heinzelmann, Clinic of Urology, UKJ
34. miRNA-expression analysis by quantitative RT-PCR in metastatic renal cell carcinoma (A31)
Brenda Henning, Clinic of Urology, UKJ
35. Regulation of APC by the COP9 signalosome (A25)
Robert Kob, Institute of Human Genetics, UKJ
36. Novel estrogen receptor interaction partners that modulates its transcriptional activity (A55)
Sonnhild Lehmann, Institute of Biochemistry II, UKJ
37. Overexpression of TLE1 is a robust diagnostic biomarker for synovial sarcomas and correlates with
t(X;18): analysis of 373 cases (A51)
Sarah Haretsch, Institute of Pathology, UKJ
38. Annexin A5 is involved in proliferation and invasion of oral carcinoma (A28)
Liane Wehder, Institute of Human Genetics, UKJ
39. Laminin chains in oral cancer: contribution to stromal matrix and vessel formation (A7)
Anke Wolheim, Institute of Pathology, UKJ
40. Snail expression in oral squamous cell carcinoma (OSCC) – correlation to nodal metastasis and
stroma activation (A9)
Karin Spiegel, Institute of Pathology, UKJ
41. Tenascin-C variants as surveillance marker for urinary bladder carcinoma (UBC) (A10)
Markus Tost, Institute of Pathology, UKJ
15.00 Uhr
Tumor genetics
Chairs: Kerstin Junker, Matthias Dürst
42. DNA damage response in T Cell Development (A46)
Amal Saidi, FLI
43. Complex formation between S100A11 and RAD54B at DNA damage sites (A17)
Ulrike Murzik, Institute of Human Genetics, UKJ
44. Tumor ploidy and gender difference in cancer survival (A40)
Susanne Schulze, Institute of Pathology, UKJ
45. Break points in chromosomes of Fanconi Anemia patients show colocalisation with so called Fragile
Sites (A1)
Christiane Schoder, Institute of Human Genetics, UKJ
46. HPV-DNA Integration as a cause of insertional mutagenesis in cervical tumors? (A44)
Martina Schmitz, Clinic of Gynecology, UKJ
47. Identification and functional investigation of genes involved in cervical carcinogenesis (A49)
Melanie Liesenfeld, Clinic of Gynecology, UKJ
48. Loss of chromosome 9 in Clear Cell Renal Cell Carcinoma: A Prognostic-Predictor? (A5)
Martin Mühr, Clinic of Urology, UKJ
49. Description of genomic imbalances in adrenocortical carcinoma (ACC) using gene chip copy number
analysis (CNA) from Affymetrix (A41)
Nicole Posorski, Institute of Human Genetics, UKJ
17.00 Uhr
Tumor cell signaling
Chairs: Otmar Huber, Aria Baniahmad
50. The tumor suppressor Fhit modulates LEF-1/TCF–ß-catenin mediated transcription (A54)
Kai Albring, Institute of Biochemistry II, UKJ
51. Regulated release of autoinhibition of Son-of-Sevenless (SOS) by ezrin-F-actin (A39)
Katja J.Geißler, FLI
52. DEFA6 expression bursts in the adenoma stage of colon carcinogenesis (A6)
Franziska Jahns, FLI
53. Calcium-activated potassium channels in human melanoma (A30)
Nicole Buttstädt, Institute of Biophysics, FSU
54. Identification of a new splice variant of the Coxsackie Adenovirus Receptor (CAR) (A45)
Marit Orlamuender, Clinic of Gynecology, UKJ
55. A novel Corepressor Inhibits Prostate Cancer Cell Growth (A26)
Claudia Gerlach, Institute of Human Genetics, UKJ
56. Inhibition of telomerase expression by androgens in the prostate (A14)
Daniela Röll, Institute of Human Genetics, UKJ
57. HDAC inhibitors induce cellular senescence in neuroblastoma and prostate cancer (A24)
Julia Roediger, Institute of Human Genetics, UKJ
18.30 Uhr
19.30 Uhr
Awards announcement
We are thankful to the following companies for sponsorship:
Bayer GmbH
Astra Zeneca
Menarini Diagnostics
Bristol-Myers Squibb
Pfizer Pharma GmbH
Die Anerkennung als ärztliche Fortbildungsveranstaltung durch die Landesärztekammer Thüringen wurde beantragt.

Vergelijkbare documenten